AAO 2023: OcuTerra provides update on Phase 2 DR:EAM diabetic retinopathy study

News
Video

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, sat down with the Eye Care Network to share clinical updates at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Hi, I'm Kerrie Brady, the president and chief executive officer of OcuTerra Therapeutics. We're delighted to be here at AAO 2023 to catch up on all the latest of what's happening in our industry. We're particularly excited to be here so that we can share news of developments at OcuTerra.

Most importantly, in the middle of this year, we announced full enrollment in our Phase 2 DR:EAM Diabetic Retinopathy Early Active Management study with our OTT166, which is a novel, selective integrin inhibitor, which has been designed to be able to be delivered as an eye drop.

So, now with full enrollment and the Phase 2 DR:EAM study, we're on schedule to have our topline results in the first quarter of next year.

Thank you.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.